Quantify the concentration of α2-macroglobulin (A2M), immunomodulatory cytokines, and TGF-β1 factors in 4 commercially available autologous blood-based products including conditioned A2M (CA2M; Alpha2EQ; Astaria Global), autologous protein solution (APS; Pro-Stride; Zoetis), platelet-rich plasma (PRP; Restigen; Zoetis), and autologous conditioned plasma (ACP; Arthrex ACP). We hypothesized that CA2M would have higher concentrations of A2M and lower concentrations of cytokines and growth factors compared to APS, PRP, and ACP. Blood was obtained from 6 healthy, adult horses and processed into CA2M, APS, PRP, and ACP. The concentration of immunomodulatory cytokines, including IL-1β, IL-4, IL-6, IL-10, IL-17a, and TNF-α, and the concentration of the growth factor TGF-β1 were quantified using immunoassays. The concentration of the IL-1 receptor antagonist was quantified using ELISA. The concentration of A2M was quantified using mass spectrometry. No differences in the concentrations of IL-1β, IL-4, IL-6, IL-10, and IL-17a were found. Median TGF-β1 was significantly higher in APS (10,801 pg/mL; P < .05), PRP (6,219 pg/mL; P < .05), and ACP (5,263 pg/mL; P < .05) compared to CA2M (2,090 pg/mL). The IL-1 receptor antagonist was significantly higher in APS (58.78 ng/mL) and PRP (40.45 ng/mL). Median A2M concentration was significantly higher in APS (4.08 mg/mL; P < .001) compared to CA2M (1.99 mg/mL). Autologous blood-based products have notably different immunomodulatory and growth factor profiles. These differences likely reflect variable concentrations of platelets and WBCs, as well as processing methods. Equine veterinarians should be aware of the constituents of the different orthobiologics available before use.
Read full abstract